Maze Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
55.5M
on 2026-06-30, from 2.45M on 2024-12-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-02-04. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
$200.0M
Jefferies, agreement of 2026-02-04. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-11 is not read yet.
Cash
15.4 quarters
$411.1M on 2026-06-30 ÷ $26.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-04-21 | Public offering incl. 0.85M pre-funded | 6,390,000 | $23.50 | $150.2M | 424B5 ↗ |
| 2025-09-10 | Private placement incl. 5.23M pre-funded | 9,231,092 | $16.25 | $150.0M | 8-K ↗ |
Also on file: $40.0M term loan, 2026-02-02 8-K ↗